129 related articles for article (PubMed ID: 10718779)
1. The effect of NAT2 genotype and gender on the metabolism of caffeine in nonsmoking subjects.
Welfare MR; Bassendine MF; Daly AK
Br J Clin Pharmacol; 2000 Mar; 49(3):240-3. PubMed ID: 10718779
[TBL] [Abstract][Full Text] [Related]
2. Quantitation of three-month intraindividual variability and influence of sex and menstrual cycle phase on CYP1A2, N-acetyltransferase-2, and xanthine oxidase activity determined with caffeine phenotyping.
Kashuba AD; Bertino JS; Kearns GL; Leeder JS; James AW; Gotschall R; Nafziger AN
Clin Pharmacol Ther; 1998 May; 63(5):540-51. PubMed ID: 9630827
[TBL] [Abstract][Full Text] [Related]
3. Comparison of CYP1A2 and NAT2 phenotypes between black and white smokers.
Muscat JE; Pittman B; Kleinman W; Lazarus P; Stellman SD; Richie JP
Biochem Pharmacol; 2008 Oct; 76(7):929-37. PubMed ID: 18703023
[TBL] [Abstract][Full Text] [Related]
4. Xanthine oxidase inhibition by allopurinol affects the reliability of urinary caffeine metabolic ratios as markers for N-acetyltransferase 2 and CYP1A2 activities.
Fuchs P; Haefeli WE; Ledermann HR; Wenk M
Eur J Clin Pharmacol; 1999 Jan; 54(11):869-76. PubMed ID: 10027663
[TBL] [Abstract][Full Text] [Related]
5. Relationship between the severity of alcoholic liver cirrhosis and the metabolism of caffeine in 226 patients.
Bechtel YC; Haffen E; Lelouët H; Brientini MP; Paintaud G; Miguet JP; Bechtel PR
Int J Clin Pharmacol Ther; 2000 Oct; 38(10):467-75. PubMed ID: 11073287
[TBL] [Abstract][Full Text] [Related]
6. Caffeine metabolic ratios for the in vivo evaluation of CYP1A2, N-acetyltransferase 2, xanthine oxidase and CYP2A6 enzymatic activities.
Hakooz NM
Curr Drug Metab; 2009 May; 10(4):329-38. PubMed ID: 19519341
[TBL] [Abstract][Full Text] [Related]
7. NAT2 and CYP1A2 phenotyping with caffeine: head-to-head comparison of AFMU vs. AAMU in the urine metabolite ratios.
Nyéki A; Buclin T; Biollaz J; Decosterd LA
Br J Clin Pharmacol; 2003 Jan; 55(1):62-7. PubMed ID: 12534641
[TBL] [Abstract][Full Text] [Related]
8. N-acetyltransferase-2 polymorphism, smoking and type 1 diabetic nephropathy.
Korpinen E; Groop PH; Rautio A; Madácsy L; Reunanen A; Vaarala O; Akerblom HK
Pharmacogenetics; 1999 Oct; 9(5):627-33. PubMed ID: 10591543
[TBL] [Abstract][Full Text] [Related]
9. Determination of CYP1A2 and NAT2 phenotypes in human populations by analysis of caffeine urinary metabolites.
Butler MA; Lang NP; Young JF; Caporaso NE; Vineis P; Hayes RB; Teitel CH; Massengill JP; Lawsen MF; Kadlubar FF
Pharmacogenetics; 1992 Jun; 2(3):116-27. PubMed ID: 1306111
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of caffeine as a test drug for CYP1A2, NAT2 and CYP2E1 phenotyping in man by in vivo versus in vitro correlations.
Fuhr U; Rost KL; Engelhardt R; Sachs M; Liermann D; Belloc C; Beaune P; Janezic S; Grant D; Meyer UA; Staib AH
Pharmacogenetics; 1996 Apr; 6(2):159-76. PubMed ID: 9156694
[TBL] [Abstract][Full Text] [Related]
11. Comparisons of CYP1A2 genetic polymorphisms, enzyme activity and the genotype-phenotype relationship in Swedes and Koreans.
Ghotbi R; Christensen M; Roh HK; Ingelman-Sundberg M; Aklillu E; Bertilsson L
Eur J Clin Pharmacol; 2007 Jun; 63(6):537-46. PubMed ID: 17370067
[TBL] [Abstract][Full Text] [Related]
12. Studies on N-Acetyltransferase (NAT2) Genotype Relationships in Emiratis: Confirmation of the Existence of Phenotype Variation among Slow Acetylators.
Al-Ahmad MM; Amir N; Dhanasekaran S; John A; Abdulrazzaq YM; Ali BR; Bastaki S
Ann Hum Genet; 2017 Sep; 81(5):190-196. PubMed ID: 28653770
[TBL] [Abstract][Full Text] [Related]
13. [Determination of caffeine metabolite for the evaluation of N-acetyltransferase, CYP1A2 and xanthine oxidase activities].
Lu JF; Yi T; Cao XM; Zhuo HT; Ling SS
Yao Xue Xue Bao; 1997 Nov; 32(11):813-8. PubMed ID: 11596199
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of caffeine as an in vivo probe for CYP1A2 using measurements in plasma, saliva, and urine.
Carrillo JA; Christensen M; Ramos SI; Alm C; Dahl ML; Benitez J; Bertilsson L
Ther Drug Monit; 2000 Aug; 22(4):409-17. PubMed ID: 10942180
[TBL] [Abstract][Full Text] [Related]
15. The effect of pregnancy on cytochrome P4501A2, xanthine oxidase, and N-acetyltransferase activities in humans.
Tsutsumi K; Kotegawa T; Matsuki S; Tanaka Y; Ishii Y; Kodama Y; Kuranari M; Miyakawa I; Nakano S
Clin Pharmacol Ther; 2001 Aug; 70(2):121-5. PubMed ID: 11503005
[TBL] [Abstract][Full Text] [Related]
16. Influence of genetic polymorphisms, smoking, gender and age on CYP1A2 activity in a Turkish population.
Gunes A; Ozbey G; Vural EH; Uluoglu C; Scordo MG; Zengil H; Dahl ML
Pharmacogenomics; 2009 May; 10(5):769-78. PubMed ID: 19450128
[TBL] [Abstract][Full Text] [Related]
17. Determination of N-acetylation phenotyping in a Greek population using caffeine as a metabolic probe.
Asprodini EK; Zifa E; Papageorgiou I; Benakis A
Eur J Drug Metab Pharmacokinet; 1998; 23(4):501-6. PubMed ID: 10323334
[TBL] [Abstract][Full Text] [Related]
18. Caffeine metabolism and the risk of spontaneous abortion of normal karyotype fetuses.
Signorello LB; Nordmark A; Granath F; Blot WJ; McLaughlin JK; Annerén G; Lundgren S; Ekbom A; Rane A; Cnattingius S
Obstet Gynecol; 2001 Dec; 98(6):1059-66. PubMed ID: 11755554
[TBL] [Abstract][Full Text] [Related]
19. Analysis of urinary caffeine metabolites to assess biotransformation enzyme activities by reversed-phase high-performance liquid chromatography.
Krul C; Hageman G
J Chromatogr B Biomed Sci Appl; 1998 May; 709(1):27-34. PubMed ID: 9653923
[TBL] [Abstract][Full Text] [Related]
20. Permanent hair dyes and bladder cancer: risk modification by cytochrome P4501A2 and N-acetyltransferases 1 and 2.
Gago-Dominguez M; Bell DA; Watson MA; Yuan JM; Castelao JE; Hein DW; Chan KK; Coetzee GA; Ross RK; Yu MC
Carcinogenesis; 2003 Mar; 24(3):483-9. PubMed ID: 12663508
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
